CargoAdmin, Bureaucrats, Moderators (CommentStreams), fileuploaders, Interface administrators, newuser, Push subscription managers, Suppressors, Administrators
5,223
edits
Pfizer: Difference between revisions
m
Text replacement - "The Guardian" to "The Guardian"
m (Text replacement - "New York City" to "New York City") |
m (Text replacement - "The Guardian" to "The Guardian") |
||
| (3 intermediate revisions by one other user not shown) | |||
| Line 79: | Line 79: | ||
In 1986, Pfizer acquired the worldwide rights to Zithromax ([[azithromycin]]), a macrolide antibiotic that is recommended by the [[Infectious Disease Society of America]] as a first line treatment for certain cases of community-acquired pneumonia, from [[Pliva]].<ref name="best">{{cite web |url=https://www.wipo.int/ipadvantage/en/details.jsp?id=906 |title=Azithromycin: A world best-selling Antibiotic |publisher=[[World Intellectual Property Organization]]}}</ref><ref>{{Cite journal |vauthors=Mandell LA, Wunderink RG, Anzueto A, etal |date=March 2007 |title=Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults |url=https://www.thoracic.org/statements/resources/mtpi/idsaats-cap.pdf |journal=Clinical Infectious Diseases |volume=44 |issue=Suppl 2 |pages=S27–72 |doi=10.1086/511159 |pmc=7107997 |pmid=17278083}}</ref> | In 1986, Pfizer acquired the worldwide rights to Zithromax ([[azithromycin]]), a macrolide antibiotic that is recommended by the [[Infectious Disease Society of America]] as a first line treatment for certain cases of community-acquired pneumonia, from [[Pliva]].<ref name="best">{{cite web |url=https://www.wipo.int/ipadvantage/en/details.jsp?id=906 |title=Azithromycin: A world best-selling Antibiotic |publisher=[[World Intellectual Property Organization]]}}</ref><ref>{{Cite journal |vauthors=Mandell LA, Wunderink RG, Anzueto A, etal |date=March 2007 |title=Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults |url=https://www.thoracic.org/statements/resources/mtpi/idsaats-cap.pdf |journal=Clinical Infectious Diseases |volume=44 |issue=Suppl 2 |pages=S27–72 |doi=10.1086/511159 |pmc=7107997 |pmid=17278083}}</ref> | ||
In 1989, Pfizer scientists Peter Dunn and Albert Wood created Viagra ([[sildenafil]]) for treating [[high blood pressure]] and [[angina]], a chest pain associated with [[coronary artery disease]]. In 1991, it was patented in the United Kingdom as a heart medication. Early trials for the medication showed that it did not work for the treatment of heart disease, but volunteers in the clinical trials had increased [[erection]]s several days after taking the drug. It was patented in the United States in 1996 and received approval by the [[Food and Drug Administration]] in March 1998. In December 1998, Pfizer hired [[Bob Dole]] as a spokesperson for the drug.<ref>{{Cite news |url=https://www.cnn.com/2013/03/27/health/viagra-anniversary-timeline/index.html |title=Viagra: The little blue pill that could |first=Jacque |last=Wilson |work=CNN |date=March 27, 2013}}</ref> The patents for Viagra expired in 2020.<ref>{{Cite news |url=https://www.theguardian.com/science/2019/jun/09/race-to-replace-viagra-patents-erectile-dysfunction-drug-medical-research-cialis-eroxon |title=The race to replace Viagra |first=David |last=Cox |work= | In 1989, Pfizer scientists Peter Dunn and Albert Wood created Viagra ([[sildenafil]]) for treating [[high blood pressure]] and [[angina]], a chest pain associated with [[coronary artery disease]]. In 1991, it was patented in the United Kingdom as a heart medication. Early trials for the medication showed that it did not work for the treatment of heart disease, but volunteers in the clinical trials had increased [[erection]]s several days after taking the drug. It was patented in the United States in 1996 and received approval by the [[Food and Drug Administration]] in March 1998. In December 1998, Pfizer hired [[Bob Dole]] as a spokesperson for the drug.<ref>{{Cite news |url=https://www.cnn.com/2013/03/27/health/viagra-anniversary-timeline/index.html |title=Viagra: The little blue pill that could |first=Jacque |last=Wilson |work=CNN |date=March 27, 2013}}</ref> The patents for Viagra expired in 2020.<ref>{{Cite news |url=https://www.theguardian.com/science/2019/jun/09/race-to-replace-viagra-patents-erectile-dysfunction-drug-medical-research-cialis-eroxon |title=The race to replace Viagra |first=David |last=Cox |work=The Guardian |date=June 9, 2019}}</ref> | ||
In 1991, [[William C. Steere, Jr.]] became [[chief executive officers]] of the company, succeeding [[Edmund T. Pratt Jr.]]<ref>{{Cite news |url=https://www.latimes.com/archives/la-xpm-1991-03-29-fi-903-story.html |title=Pfizer Inc., New York, has elected its... |work= | In 1991, [[William C. Steere, Jr.]] became [[chief executive officers]] of the company, succeeding [[Edmund T. Pratt Jr.]]<ref>{{Cite news |url=https://www.latimes.com/archives/la-xpm-1991-03-29-fi-903-story.html |title=Pfizer Inc., New York, has elected its... |work=Los Angeles Times |date=March 29, 1991}}</ref> | ||
In 1991 Pfizer also began marketing Zoloft ([[sertraline]]), an [[antidepressant]] of the [[selective serotonin reuptake inhibitor]] (SSRI) class developed nine years earlier by Pfizer chemists [[Kenneth Koe]] and Willard Welch. Sertraline is primarily prescribed for [[major depressive disorder]] in adult [[outpatients]] as well as [[obsessive-compulsive disorder]], [[panic disorder]], and [[social anxiety disorder]] in both adults and children. In 2005, the year before it became a generic drug, sales were over $3{{nbsp}}billion and over 100{{nbsp}}million people had been treated with the drug.<ref>{{Cite web |date=December 2015 |title=Kenneth Koe '45 |url=https://www.reed.edu/reed-magazine/in-memoriam/obituaries/_online_only/kenneth-koe-1945.html |url-status=live |access-date=2021-05-18 |website=Reed Magazine |publisher=[[Reed College]] |archive-url=https://web.archive.org/web/20220414055337/https://www.reed.edu/reed-magazine/in-memoriam/obituaries/_online_only/kenneth-koe-1945.html |archive-date=2022-04-14}}</ref> The patent for Zoloft expired in the summer of 2006.<ref>{{Cite news |last=Smith |first=Aaron |date=2006-04-04 |title=Who stands to gain when Zoloft goes generic? |work=[[CNN Money]] |url=https://money.cnn.com/2006/04/04/news/companies/antidepressants/ |access-date=2021-05-18}}</ref> | In 1991 Pfizer also began marketing Zoloft ([[sertraline]]), an [[antidepressant]] of the [[selective serotonin reuptake inhibitor]] (SSRI) class developed nine years earlier by Pfizer chemists [[Kenneth Koe]] and Willard Welch. Sertraline is primarily prescribed for [[major depressive disorder]] in adult [[outpatients]] as well as [[obsessive-compulsive disorder]], [[panic disorder]], and [[social anxiety disorder]] in both adults and children. In 2005, the year before it became a generic drug, sales were over $3{{nbsp}}billion and over 100{{nbsp}}million people had been treated with the drug.<ref>{{Cite web |date=December 2015 |title=Kenneth Koe '45 |url=https://www.reed.edu/reed-magazine/in-memoriam/obituaries/_online_only/kenneth-koe-1945.html |url-status=live |access-date=2021-05-18 |website=Reed Magazine |publisher=[[Reed College]] |archive-url=https://web.archive.org/web/20220414055337/https://www.reed.edu/reed-magazine/in-memoriam/obituaries/_online_only/kenneth-koe-1945.html |archive-date=2022-04-14}}</ref> The patent for Zoloft expired in the summer of 2006.<ref>{{Cite news |last=Smith |first=Aaron |date=2006-04-04 |title=Who stands to gain when Zoloft goes generic? |work=[[CNN Money]] |url=https://money.cnn.com/2006/04/04/news/companies/antidepressants/ |access-date=2021-05-18}}</ref> | ||
| Line 99: | Line 99: | ||
In July 2006, [[Jeff Kindler]] was named [[chief executive officer]] of the company, replacing [[Henry McKinnell]].<ref name="longshot" /><ref>{{Cite news |date=July 28, 2006 |title=Pfizer names new CEO |work=CNN |url=https://money.cnn.com/2006/07/28/news/companies/pfizer_ceo/index.htm}}</ref> | In July 2006, [[Jeff Kindler]] was named [[chief executive officer]] of the company, replacing [[Henry McKinnell]].<ref name="longshot" /><ref>{{Cite news |date=July 28, 2006 |title=Pfizer names new CEO |work=CNN |url=https://money.cnn.com/2006/07/28/news/companies/pfizer_ceo/index.htm}}</ref> | ||
On December 3, 2006, Pfizer ceased development of [[torcetrapib]], a drug that increases production of [[high density lipoprotein|HDL]], which reduces [[low density lipoprotein|LDL]] thought to be correlated to heart disease. During a [[Phase III clinical trial]] involving 15,000 patients, more deaths than expected occurred in the group that took the medicine, and the [[mortality rate]] of patients taking the combination of torcetrapib and Lipitor (82 deaths during the study) was 60% higher than those taking Lipitor alone (52 deaths during the study). Lipitor alone was not implicated in the results, but Pfizer lost nearly $1{{nbsp}}billion developing the failed drug and its stock price dropped 11% on the day of the announcement.<ref>{{Cite news |last1=Berenson |first1=Alex |last2=Pollack |first2=Andrew |date=December 5, 2006 |title=Pfizer Shares Plummet on Loss of a Promising Heart Drug |work=The New York Times |url=https://www.nytimes.com/2006/12/05/health/05pfizer.html |url-access=limited}}</ref><ref>{{Cite news |last=Berenson |first=Alex |date=December 3, 2006 |title=Pfizer Ends Studies on Drug for Heart Disease |work=The New York Times |url=https://www.nytimes.com/2006/12/03/health/03pfizer.html |url-access=limited |authorlink=Alex Berenson}}</ref><ref>{{Cite news |last=Agovino |first=Theresa |date=December 3, 2006 |title=Pfizer ends cholesterol drug development |publisher=[[The Seattle Times]] |agency= | On December 3, 2006, Pfizer ceased development of [[torcetrapib]], a drug that increases production of [[high density lipoprotein|HDL]], which reduces [[low density lipoprotein|LDL]] thought to be correlated to heart disease. During a [[Phase III clinical trial]] involving 15,000 patients, more deaths than expected occurred in the group that took the medicine, and the [[mortality rate]] of patients taking the combination of torcetrapib and Lipitor (82 deaths during the study) was 60% higher than those taking Lipitor alone (52 deaths during the study). Lipitor alone was not implicated in the results, but Pfizer lost nearly $1{{nbsp}}billion developing the failed drug and its stock price dropped 11% on the day of the announcement.<ref>{{Cite news |last1=Berenson |first1=Alex |last2=Pollack |first2=Andrew |date=December 5, 2006 |title=Pfizer Shares Plummet on Loss of a Promising Heart Drug |work=The New York Times |url=https://www.nytimes.com/2006/12/05/health/05pfizer.html |url-access=limited}}</ref><ref>{{Cite news |last=Berenson |first=Alex |date=December 3, 2006 |title=Pfizer Ends Studies on Drug for Heart Disease |work=The New York Times |url=https://www.nytimes.com/2006/12/03/health/03pfizer.html |url-access=limited |authorlink=Alex Berenson}}</ref><ref>{{Cite news |last=Agovino |first=Theresa |date=December 3, 2006 |title=Pfizer ends cholesterol drug development |publisher=[[The Seattle Times]] |agency=Associated Press |url=https://www.seattletimes.com/nation-world/cholesterol-drug-trials-are-halted/}}</ref><ref>{{cite journal |last1=Tanne |first1=Janice Hopkins |title=Pfizer stops clinical trials of heart drug |journal=BMJ |date=16 December 2006 |volume=333 |issue=7581 |pages=1237.2–1237 |doi=10.1136/bmj.39059.438044.DB |pmid=17170401 |pmc=1702474}}</ref> | ||
Between 2007 and 2010, Pfizer spent $3.3{{nbsp}}million on investigations and legal fees and recovered about $5.1{{nbsp}}million, and had another $5{{nbsp}}million of pending recoveries from civil lawsuits against makers of [[counterfeit]] prescription drugs. Pfizer has hired customs and narcotics experts worldwide to track down fakes and assemble evidence that can be used to pursue civil suits for [[trademark infringement]].<ref>{{Cite news |last=Bennett |first=Simeon |date=July 8, 2010 |title=Pfizer: Civil Suits for Drug Counterfeiters |work=[[Bloomberg Businessweek]] |url=https://www.bloomberg.com/news/articles/2010-07-08/pfizer-civil-suits-for-drug-counterfeiters |url-access=limited}}</ref> | Between 2007 and 2010, Pfizer spent $3.3{{nbsp}}million on investigations and legal fees and recovered about $5.1{{nbsp}}million, and had another $5{{nbsp}}million of pending recoveries from civil lawsuits against makers of [[counterfeit]] prescription drugs. Pfizer has hired customs and narcotics experts worldwide to track down fakes and assemble evidence that can be used to pursue civil suits for [[trademark infringement]].<ref>{{Cite news |last=Bennett |first=Simeon |date=July 8, 2010 |title=Pfizer: Civil Suits for Drug Counterfeiters |work=[[Bloomberg Businessweek]] |url=https://www.bloomberg.com/news/articles/2010-07-08/pfizer-civil-suits-for-drug-counterfeiters |url-access=limited}}</ref> | ||
| Line 110: | Line 110: | ||
In 2003, Pfizer merged with [[Pharmacia]], and in the process acquired [[G.D. Searle, LLC|Searle]] and [[SUGEN]]. Searle had developed Flagyl ([[metronidazole]]), a [[nitroimidazole]] antibiotic medication used particularly for [[anaerobe|anaerobic]] [[bacterium|bacteria]] and [[protozoa]].<ref name=":0" /><ref>{{Cite web |title=Metronidazole Monograph for Professionals |url=https://www.drugs.com/monograph/metronidazole.html |publisher=[[Drugs.com]]}}</ref> Searle also developed [[celecoxib]] (Celebrex) a [[COX-2 inhibitor]] and [[nonsteroidal anti-inflammatory drug]] (NSAID) used to treat the [[pain]] and [[inflammation]] in [[osteoarthritis]], [[acute pain]] in adults, [[rheumatoid arthritis]], [[ankylosing spondylitis]], [[painful menstruation]], and [[juvenile rheumatoid arthritis]].<ref>{{cite web |date=11 November 2019 |title=Celecoxib Monograph for Professionals |url=https://www.drugs.com/monograph/celecoxib.html |website=Drugs.com |publisher=American Society of Health-System Pharmacists}}</ref> [[SUGEN]], a company focused on [[protein kinase]] inhibitors, had pioneered the use of ATP-mimetic small molecules to block [[signal transduction]]. The [[SUGEN]] facility was shut down in 2003 by Pfizer, with the loss of more than 300 jobs, and several programs were transferred to Pfizer. These included [[sunitinib]] (Sutent), a cancer medication which was approved for human use by the FDA in January 2006.<ref>{{Cite news |url=https://www.bloomberg.com/news/articles/2005-11-20/the-spirit-of-a-startup-lives-on |title=The Spirit Of A Startup Lives On |work=[[Bloomberg Businessweek]] |date=November 21, 2005}}</ref><ref>{{Cite news |url=https://www.bizjournals.com/sanfrancisco/stories/2003/04/28/daily24.html |title=Pfizer expects to shutter South City biotech outpost |work=[[American City Business Journals]] |date=April 30, 2003}}</ref> A related compound, SU11654 ([[Toceranib]]), was also approved for [[cancer in dogs]], and the [[ALK inhibitor]] [[Crizotinib]] also grew out of a SUGEN program.<ref>{{Cite news |url=https://www.wsj.com/articles/SB10001424053111904009304576532892704206326 |title=FDA Approves Pfizer Lung-Cancer Drug |first=Jonathan D. |last=Rockoff |work=The Wall Street Journal |date=August 26, 2011 |url-access=subscription}}</ref><ref>{{cite book |doi=10.1016/B978-0-12-409547-2.12391-1 |chapter=Selective Kinase Inhibitors in Cancer |title=Comprehensive Medicinal Chemistry III |year=2017 |last1=Mortlock |first1=A.A. |last2=Wilson |first2=D.M. |last3=Kettle |first3=J.G. |last4=Goldberg |first4=F.W. |last5=Foote |first5=K.M. |pages=39–75 |isbn=978-0-12-803201-5}}</ref> | In 2003, Pfizer merged with [[Pharmacia]], and in the process acquired [[G.D. Searle, LLC|Searle]] and [[SUGEN]]. Searle had developed Flagyl ([[metronidazole]]), a [[nitroimidazole]] antibiotic medication used particularly for [[anaerobe|anaerobic]] [[bacterium|bacteria]] and [[protozoa]].<ref name=":0" /><ref>{{Cite web |title=Metronidazole Monograph for Professionals |url=https://www.drugs.com/monograph/metronidazole.html |publisher=[[Drugs.com]]}}</ref> Searle also developed [[celecoxib]] (Celebrex) a [[COX-2 inhibitor]] and [[nonsteroidal anti-inflammatory drug]] (NSAID) used to treat the [[pain]] and [[inflammation]] in [[osteoarthritis]], [[acute pain]] in adults, [[rheumatoid arthritis]], [[ankylosing spondylitis]], [[painful menstruation]], and [[juvenile rheumatoid arthritis]].<ref>{{cite web |date=11 November 2019 |title=Celecoxib Monograph for Professionals |url=https://www.drugs.com/monograph/celecoxib.html |website=Drugs.com |publisher=American Society of Health-System Pharmacists}}</ref> [[SUGEN]], a company focused on [[protein kinase]] inhibitors, had pioneered the use of ATP-mimetic small molecules to block [[signal transduction]]. The [[SUGEN]] facility was shut down in 2003 by Pfizer, with the loss of more than 300 jobs, and several programs were transferred to Pfizer. These included [[sunitinib]] (Sutent), a cancer medication which was approved for human use by the FDA in January 2006.<ref>{{Cite news |url=https://www.bloomberg.com/news/articles/2005-11-20/the-spirit-of-a-startup-lives-on |title=The Spirit Of A Startup Lives On |work=[[Bloomberg Businessweek]] |date=November 21, 2005}}</ref><ref>{{Cite news |url=https://www.bizjournals.com/sanfrancisco/stories/2003/04/28/daily24.html |title=Pfizer expects to shutter South City biotech outpost |work=[[American City Business Journals]] |date=April 30, 2003}}</ref> A related compound, SU11654 ([[Toceranib]]), was also approved for [[cancer in dogs]], and the [[ALK inhibitor]] [[Crizotinib]] also grew out of a SUGEN program.<ref>{{Cite news |url=https://www.wsj.com/articles/SB10001424053111904009304576532892704206326 |title=FDA Approves Pfizer Lung-Cancer Drug |first=Jonathan D. |last=Rockoff |work=The Wall Street Journal |date=August 26, 2011 |url-access=subscription}}</ref><ref>{{cite book |doi=10.1016/B978-0-12-409547-2.12391-1 |chapter=Selective Kinase Inhibitors in Cancer |title=Comprehensive Medicinal Chemistry III |year=2017 |last1=Mortlock |first1=A.A. |last2=Wilson |first2=D.M. |last3=Kettle |first3=J.G. |last4=Goldberg |first4=F.W. |last5=Foote |first5=K.M. |pages=39–75 |isbn=978-0-12-803201-5}}</ref> | ||
In October 2006, the company announced it would acquire PowerMed.<ref>{{Cite news |last=Barriaux |first=Marianne |date=October 9, 2006 |title=Pfizer buys vaccine developer PowderMed |work= | In October 2006, the company announced it would acquire PowerMed.<ref>{{Cite news |last=Barriaux |first=Marianne |date=October 9, 2006 |title=Pfizer buys vaccine developer PowderMed |work=The Guardian |url=https://www.theguardian.com/business/2006/oct/09/money5}}</ref> | ||
On October 15, 2009, Pfizer acquired [[Wyeth]] for $68{{nbsp}}billion in cash and stock, including the assumption of debt, making Pfizer the largest pharmaceutical company in the world.<ref>{{Cite news |last1=Sorkin |first1=Andrew Ross |last2=Wilson |first2=Duff |date=January 25, 2009 |title=Pfizer Agrees to Pay $68 Billion for Rival Drug Maker Wyeth |work=The New York Times |url=https://www.nytimes.com/2009/01/26/business/26drug.html |url-access=limited |issn=0362-4331 |authorlink1=Andrew Ross Sorkin |authorlink2=Duff Wilson}}</ref><ref>{{Cite news |date=October 15, 2009 |title=Pfizer completes $67 billion deal for rival Wyeth |work= | On October 15, 2009, Pfizer acquired [[Wyeth]] for $68{{nbsp}}billion in cash and stock, including the assumption of debt, making Pfizer the largest pharmaceutical company in the world.<ref>{{Cite news |last1=Sorkin |first1=Andrew Ross |last2=Wilson |first2=Duff |date=January 25, 2009 |title=Pfizer Agrees to Pay $68 Billion for Rival Drug Maker Wyeth |work=The New York Times |url=https://www.nytimes.com/2009/01/26/business/26drug.html |url-access=limited |issn=0362-4331 |authorlink1=Andrew Ross Sorkin |authorlink2=Duff Wilson}}</ref><ref>{{Cite news |date=October 15, 2009 |title=Pfizer completes $67 billion deal for rival Wyeth |work=Reuters |url=https://www.reuters.com/article/instant-article/idUSTRE59E4S320091015}}</ref><ref>{{cite news |last1=Karnitschnig |first1=Matthew |last2=Rockoff |first2=Jonathan D. |date=January 23, 2009 |title=Pfizer in Talks to Buy Wyeth |work=The Wall Street Journal |url=https://www.wsj.com/articles/SB123268511212809429 |url-access=subscription}}</ref><ref name="worst">{{Cite news |last=Edwards |first=Jim |date=January 23, 2009 |title=The Pfizer–Wyeth Deal Worst-Case Scenario |work=[[CBS News]] |url=https://www.cbsnews.com/news/the-pfizer-wyeth-deal-worst-case-scenario/}}</ref><ref name="wyethpr">{{Cite press release |title=PFIZER COMPLETES ACQUISITION OF WYETH |url=https://www.pfizer.com/news/press-release/press-release-detail/pfizer_completes_acquisition_of_wyeth |publisher=Pfizer |date=October 14, 2009}}</ref> The acquisition of Wyeth provided Pfizer with a [[pneumococcal conjugate vaccine]], trademarked [[Pneumococcal conjugate vaccine#Prevnar|Prevnar 13]]; this is used for the prevention of invasive pneumococcal infections. The introduction of the original, 7-valent version of the vaccine, developed by [[Wyeth]] in February 2000, led to a 75% reduction in the incidence of invasive pneumococcal infections among children under age{{nbsp}}5 in the United States. Pfizer introduced an improved version of the vaccine in 2010, for which it was granted a patent in India in 2017. Prevnar 13 provides coverage of 13 bacterial variants, expanding beyond the original 7-valent version.<ref name="wyethpr" /> By 2012, the rate of invasive infections among children under age{{spaces}}5 had been reduced by an additional 50%.<ref name="cdc.gov">{{Cite web |date=April 5, 2019 |title=CDC – ABCs: Surveillance Reports main page – Active Bacterial Core surveillance |url=https://www.cdc.gov/abcs/reports-findings/surv-reports.html}}</ref><ref>{{Cite web |last=Herper |first=Matthew |date=August 24, 2020 |title=In the race for a Covid-19 vaccine, Pfizer turns to a scientist with a history of defying skeptics – and getting results |url=https://www.statnews.com/2020/08/24/pfizer-edge-in-the-race-for-a-covid-19-vaccine-could-be-a-scientist-with-two-best-sellers-to-her-credit/ |website=[[Stat (website)|Stat]]}}</ref> | ||
=== 2010–2020: Further discoveries and acquisitions === | === 2010–2020: Further discoveries and acquisitions === | ||
| Line 120: | Line 120: | ||
In February 2011, Pfizer announced the closure of its UK research and development facility (formerly also a manufacturing plant) in [[Sandwich, Kent]], which at the time employed 2,400 people.<ref>{{Cite news |url=https://www.bbc.co.uk/news/business-12335801 |title=Pfizer to close UK research site |work=[[BBC News]] |date=February 1, 2011}}</ref> In March 2011, Pfizer acquired [[King Pharmaceuticals]] for $3.6{{nbsp}}billion in cash. King produced emergency injectables such as the [[EpiPen]].<ref>{{Cite news |url=https://www.modernhealthcare.com/article/20110301/NEWS/303019922/pfizer-closes-king-pharmaceuticals-acquisition |title=Pfizer closes King Pharmaceuticals acquisition |first=Maureen |last=Mckinney |work=[[Modern Healthcare]] |date=March 1, 2011}}</ref> | In February 2011, Pfizer announced the closure of its UK research and development facility (formerly also a manufacturing plant) in [[Sandwich, Kent]], which at the time employed 2,400 people.<ref>{{Cite news |url=https://www.bbc.co.uk/news/business-12335801 |title=Pfizer to close UK research site |work=[[BBC News]] |date=February 1, 2011}}</ref> In March 2011, Pfizer acquired [[King Pharmaceuticals]] for $3.6{{nbsp}}billion in cash. King produced emergency injectables such as the [[EpiPen]].<ref>{{Cite news |url=https://www.modernhealthcare.com/article/20110301/NEWS/303019922/pfizer-closes-king-pharmaceuticals-acquisition |title=Pfizer closes King Pharmaceuticals acquisition |first=Maureen |last=Mckinney |work=[[Modern Healthcare]] |date=March 1, 2011}}</ref> | ||
On September 4, 2012, the FDA approved [[bosutinib]] (Bosulif) for [[chronic myelogenous leukemia]] (CML), a rare type of [[leukemia]] and a blood and [[bone marrow]] disease that affects primarily older adults.<ref>{{Cite news |url=https://www.reuters.com/article/us-pfizer-leukemia/fda-approves-pfizer-leukemia-drug-idUSBRE88314720120904 |title=FDA approves Pfizer leukemia drug |first=Anna |last=Yukhananov |work= | On September 4, 2012, the FDA approved [[bosutinib]] (Bosulif) for [[chronic myelogenous leukemia]] (CML), a rare type of [[leukemia]] and a blood and [[bone marrow]] disease that affects primarily older adults.<ref>{{Cite news |url=https://www.reuters.com/article/us-pfizer-leukemia/fda-approves-pfizer-leukemia-drug-idUSBRE88314720120904 |title=FDA approves Pfizer leukemia drug |first=Anna |last=Yukhananov |work=Reuters |date=September 4, 2012}}</ref> In November 2012, Pfizer received approval from the [[Food and Drug Administration]] for Xeljanz, a [[tofacitinib]], for [[rheumatoid arthritis]] and [[ulcerative colitis]].<ref>{{Cite web |url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203214orig1s000toc.cfm |title=Drug Approval Package |publisher=[[Food and Drug Administration]]}}</ref> The drug had sales of $1.77{{nbsp}}billion in 2018, and in January 2019, it was the top drug in the United States for [[direct-to-consumer advertising]], passing [[adalimumab]] (Humira).<ref>{{Cite magazine |title=Pfizer switches RA patients to lower dose of fast-growing Xeljanz as safety issues arise in postmarketing study |url=https://www.fiercepharma.com/pharma/postmarketing-study-pfizer-switches-ra-patients-to-lower-xeljanz-dose-safety-concerns |magazine=Fierce Pharma |first=Eric |last=Sagonowsky |date=February 20, 2019}}</ref> | ||
On February 1, 2013, [[Zoetis]], the Agriculture Division of Pfizer and later Pfizer Animal Health, became a [[public company]] via an [[initial public offering]], raising $2.2{{nbsp}}billion.<ref>{{Cite press release |title=Zoetis™ Files IPO Registration Statement |url=https://www.zoetisus.com/news-and-media/zoetis-files-ipo-registration-statement.aspx |publisher=[[Business Wire]] |date=August 13, 2012}}</ref><ref>{{Cite news |url=https://dealbook.nytimes.com/2013/02/01/shares-of-zoetis-surge-on-debut/ |last=J. de la Merced |first=Michael |title=Shares of Zoetis Surge on Debut |work=The New York Times |date=February 1, 2013 |url-access=limited}}</ref><ref>{{Cite news |title=Zoetis Raises $2.2 Billion in IPO |url=https://www.wsj.com/articles/SB10001424127887323701904578276530830057770 |last=Dieterich |first=Chris |work=The Wall Street Journal |date=January 31, 2013 |url-access=subscription}}</ref><ref>{{Cite news |url=https://www.cbsnews.com/news/shares-of-animal-health-company-zoetis-soar-in-ipo/ |title=Shares of animal health company Zoetis soar in IPO |agency= | On February 1, 2013, [[Zoetis]], the Agriculture Division of Pfizer and later Pfizer Animal Health, became a [[public company]] via an [[initial public offering]], raising $2.2{{nbsp}}billion.<ref>{{Cite press release |title=Zoetis™ Files IPO Registration Statement |url=https://www.zoetisus.com/news-and-media/zoetis-files-ipo-registration-statement.aspx |publisher=[[Business Wire]] |date=August 13, 2012}}</ref><ref>{{Cite news |url=https://dealbook.nytimes.com/2013/02/01/shares-of-zoetis-surge-on-debut/ |last=J. de la Merced |first=Michael |title=Shares of Zoetis Surge on Debut |work=The New York Times |date=February 1, 2013 |url-access=limited}}</ref><ref>{{Cite news |title=Zoetis Raises $2.2 Billion in IPO |url=https://www.wsj.com/articles/SB10001424127887323701904578276530830057770 |last=Dieterich |first=Chris |work=The Wall Street Journal |date=January 31, 2013 |url-access=subscription}}</ref><ref>{{Cite news |url=https://www.cbsnews.com/news/shares-of-animal-health-company-zoetis-soar-in-ipo/ |title=Shares of animal health company Zoetis soar in IPO |agency=Associated Press |publisher=[[CBS News]] |date=February 1, 2013}}</ref> Later in 2013, Pfizer completed the [[corporate spin-off]] of its remaining stake in [[Zoetis]].<ref>{{Cite news |url=https://www.wsj.com/articles/SB10001424127887323975004578498994013821124 |title=Pfizer to Spin Off Remaining Zoetis Stake |first=Peter |last=Loftus |work=The Wall Street Journal |date=May 22, 2013}}</ref><ref>{{Cite news |url=https://www.reuters.com/article/us-pfizer-zoetis/pfizer-to-spin-off-zoetis-stake-to-shareholders-idUSBRE94L0JB20130522 |title=Pfizer to spin off Zoetis stake to shareholders |first1=Caroline |last1=Humer |first2=Ransdell |last2=Pierson |work=Reuters |date=May 22, 2013}}</ref> | ||
In September 2014, the company acquired Innopharma for $225{{nbsp}}million, plus up to $135{{nbsp}}million in milestone payments, in a deal that expanded Pfizer's range of generic and injectable drugs.<ref>{{Cite magazine |url=https://www.fiercepharma.com/pharma/pfizer-completes-acquisition-of-innopharma |title=Pfizer Completes Acquisition Of InnoPharma |first=Emily |last=Wasserman |magazine=Fierce Pharma |date=September 29, 2014}}</ref><ref>{{Cite news |title=Pfizer to Acquire InnoPharma for Up to $360M |url=https://www.genengnews.com/news/pfizer-to-acquire-innopharma-for-up-to-360m/ |website=genengnews.com |date=July 16, 2014}}</ref> | In September 2014, the company acquired Innopharma for $225{{nbsp}}million, plus up to $135{{nbsp}}million in milestone payments, in a deal that expanded Pfizer's range of generic and injectable drugs.<ref>{{Cite magazine |url=https://www.fiercepharma.com/pharma/pfizer-completes-acquisition-of-innopharma |title=Pfizer Completes Acquisition Of InnoPharma |first=Emily |last=Wasserman |magazine=Fierce Pharma |date=September 29, 2014}}</ref><ref>{{Cite news |title=Pfizer to Acquire InnoPharma for Up to $360M |url=https://www.genengnews.com/news/pfizer-to-acquire-innopharma-for-up-to-360m/ |website=genengnews.com |date=July 16, 2014}}</ref> | ||
On January 5, 2015, the company announced it would acquire a controlling interest in Redvax, expanding its vaccine portfolio targeting human [[cytomegalovirus]].<ref>{{Cite news |title=Pfizer Buys Redvax, Boosting Vaccine Portfolio |url=https://www.genengnews.com/topics/drug-discovery/pfizer-buys-redvax-boosting-vaccine-portfolio/ |website=genengnews.com |date=January 5, 2015}}</ref> In February 2015, the company received approval from the [[Food and Drug Administration]] for [[palbociclib]] (Ibrance) for treatment of certain types of [[breast cancer]].<ref>{{cite journal |last1=Beaver |first1=Julia A. |last2=Amiri-Kordestani |first2=Laleh |last3=Charlab |first3=Rosane |last4=Chen |first4=Wei |last5=Palmby |first5=Todd |last6=Tilley |first6=Amy |last7=Zirkelbach |first7=Jeanne Fourie |last8=Yu |first8=Jingyu |last9=Liu |first9=Qi |last10=Zhao |first10=Liang |last11=Crich |first11=Joyce |last12=Chen |first12=Xiao Hong |last13=Hughes |first13=Minerva |last14=Bloomquist |first14=Erik |last15=Tang |first15=Shenghui |last16=Sridhara |first16=Rajeshwari |last17=Kluetz |first17=Paul G. |last18=Kim |first18=Geoffrey |last19=Ibrahim |first19=Amna |last20=Pazdur |first20=Richard |last21=Cortazar |first21=Patricia |title=FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer |journal=Clinical Cancer Research |date=1 November 2015 |volume=21 |issue=21 |pages=4760–4766 |doi=10.1158/1078-0432.CCR-15-1185 |pmid=26324739 |s2cid=24762535 |doi-access=free}}</ref><ref>{{Cite web |url=https://www.fda.gov/drugs/resources-information-approved-drugs/palbociclib-ibrance |title=Palbociclib (IBRANCE) |date=February 9, 2019 |publisher=[[Food and Drug Administration]]}}</ref> In March 2015, the company announced it would restart its collaboration with [[Eli Lilly and Company]] surrounding the [[Phase III trial]] of [[Tanezumab]].<ref>{{Cite news |title=Pfizer, Lilly to Resume Phase III Tanezumab Clinical Program |url=https://www.genengnews.com/topics/drug-discovery/pfizer-lilly-to-resume-phase-iii-tanezumab-clinical-program/ |website=genengnews.com |date=March 23, 2015}}</ref> In May 2015, Pfizer and a [[Bar-Ilan University]] laboratory announced a partnership based on the development of medical [[DNA nanotechnology]].<ref>{{Cite news |last=Gali |first=Weinreb |title=Pfizer to collaborate on Bar-Ilan DNA robots |work=[[Globes (newspaper)|Globes]] |url=https://en.globes.co.il/en/article-pfizer-to-collaborate-on-bar-ilan-dna-robots-1001036703 |date=May 14, 2015}}</ref> In June 2015, the company acquired Nimenrix and Mencevax, [[meningococcal vaccine]]s, from GlaxoSmithKline for around $130{{nbsp}}million.<ref>{{Cite news |title=Pfizer Buys Two GSK Meningitis Vaccines for $130M |url=https://www.genengnews.com/topics/drug-discovery/pfizer-buys-two-gsk-meningitis-vaccines-for-130m/ |website=genengnews.com |date=June 22, 2015}}</ref> In September 2015, Pfizer acquired [[Hospira]] for $17{{nbsp}}billion, including the assumption of debt.<ref>{{Cite press release |url=https://www.businesswire.com/news/home/20150903005752/en/Pfizer-Completes-Acquisition-of-Hospira |title=Pfizer Completes Acquisition of Hospira |publisher=Pfizer |via=[[Business Wire]] |date=September 3, 2015}}</ref><ref>{{Cite news |url=https://www.thepharmaletter.com/article/pfizer-completes-17-billion-hospira-acquisition |title=Pfizer completes $17-billion Hospira acquisition |work=[[The Pharma Letter]] |date=September 4, 2015}}</ref><ref>{{Cite news |first1=David |last1=Gelles |first2=Katie |last2=Thomas |title=Pfizer Bets $15 Billion on New Class of Generic Drugs |url=https://dealbook.nytimes.com/2015/02/05/pfizer-to-buy-hospira-a-drug-maker-for-15-2-billion-in-cash |work=The New York Times |date=February 5, 2015 |url-access=limited}}</ref><ref>{{Cite web |title=8-K |url=https://www.sec.gov/Archives/edgar/data/78003/000119312515037588/d866443d8k.htm |publisher=[[U.S. Securities and Exchange Commission]] |date=February 6, 2015}}</ref><ref>{{Cite press release |title=Pfizer to Acquire Hospira |url=https://www.pfizer.com/news/press-release/press-release-detail/pfizer_to_acquire_hospira |work=Pfizer |access-date=May 1, 2021 |archive-date=April 26, 2021 |archive-url=https://web.archive.org/web/20210426025941/https://www.pfizer.com/news/press-release/press-release-detail/pfizer_to_acquire_hospira |url-status=dead }}</ref><ref>{{Cite news |last=Neilan |first=Catherine |title=Pfizer, Hospira share prices to soar after $17bn deal announced |url=https://www.cityam.com/pfizer-hospira-share-prices-soar-after-17bn-deal-announced/ |work=[[City A.M.]] |date=February 5, 2015}}</ref> [[Hospira]] was the largest producer of generic injectable pharmaceuticals in the world.<ref>{{Cite news |title=US-based Hospira to buy Orchid Chemicals' injectables biz for $400 mn |url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/us-based-hospira-to-buy-orchid-chemicals-injectables-biz-for-400-mn/articleshow/5342003.cms |first1=Mohit |last1=Bhalla |first2=Khomba |last2=Singh |work=[[The Economic Times]] |date=December 16, 2009}}</ref> On November 23, 2015, Pfizer and [[Allergan]] announced a planned $160{{nbsp}}billion merger, in the largest pharmaceutical deal ever and the third largest corporate merger in history. The proposed transaction contemplated that the merged company maintain Allergan's [[Republic of Ireland]] domicile, resulting in the new company being subject to [[corporation tax]] at the relatively low rate of 12.5%.<ref>{{Cite news |title=Pfizer seals $160bn Allergan deal to create drugs giant |url=https://www.bbc.co.uk/news/business-34900344 |work=[[BBC News]] |date=November 23, 2015}}</ref> The deal was to constitute a [[reverse merger]], whereby Allergan acquired Pfizer, with the new company then changing its name to "Pfizer, plc".<ref>{{Cite news |title=Pfizer to buy Allergan in $160 billion deal |url=https://www.reuters.com/article/us-allergan-m-a-pfizer/pfizer-to-buy-allergan-in-160-billion-deal-idUSKBN0TB0UT20151124 |first1=Ransdell |last1=Pierson |first2=Bill |last2=Berkrot |work= | On January 5, 2015, the company announced it would acquire a controlling interest in Redvax, expanding its vaccine portfolio targeting human [[cytomegalovirus]].<ref>{{Cite news |title=Pfizer Buys Redvax, Boosting Vaccine Portfolio |url=https://www.genengnews.com/topics/drug-discovery/pfizer-buys-redvax-boosting-vaccine-portfolio/ |website=genengnews.com |date=January 5, 2015}}</ref> In February 2015, the company received approval from the [[Food and Drug Administration]] for [[palbociclib]] (Ibrance) for treatment of certain types of [[breast cancer]].<ref>{{cite journal |last1=Beaver |first1=Julia A. |last2=Amiri-Kordestani |first2=Laleh |last3=Charlab |first3=Rosane |last4=Chen |first4=Wei |last5=Palmby |first5=Todd |last6=Tilley |first6=Amy |last7=Zirkelbach |first7=Jeanne Fourie |last8=Yu |first8=Jingyu |last9=Liu |first9=Qi |last10=Zhao |first10=Liang |last11=Crich |first11=Joyce |last12=Chen |first12=Xiao Hong |last13=Hughes |first13=Minerva |last14=Bloomquist |first14=Erik |last15=Tang |first15=Shenghui |last16=Sridhara |first16=Rajeshwari |last17=Kluetz |first17=Paul G. |last18=Kim |first18=Geoffrey |last19=Ibrahim |first19=Amna |last20=Pazdur |first20=Richard |last21=Cortazar |first21=Patricia |title=FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer |journal=Clinical Cancer Research |date=1 November 2015 |volume=21 |issue=21 |pages=4760–4766 |doi=10.1158/1078-0432.CCR-15-1185 |pmid=26324739 |s2cid=24762535 |doi-access=free}}</ref><ref>{{Cite web |url=https://www.fda.gov/drugs/resources-information-approved-drugs/palbociclib-ibrance |title=Palbociclib (IBRANCE) |date=February 9, 2019 |publisher=[[Food and Drug Administration]]}}</ref> In March 2015, the company announced it would restart its collaboration with [[Eli Lilly and Company]] surrounding the [[Phase III trial]] of [[Tanezumab]].<ref>{{Cite news |title=Pfizer, Lilly to Resume Phase III Tanezumab Clinical Program |url=https://www.genengnews.com/topics/drug-discovery/pfizer-lilly-to-resume-phase-iii-tanezumab-clinical-program/ |website=genengnews.com |date=March 23, 2015}}</ref> In May 2015, Pfizer and a [[Bar-Ilan University]] laboratory announced a partnership based on the development of medical [[DNA nanotechnology]].<ref>{{Cite news |last=Gali |first=Weinreb |title=Pfizer to collaborate on Bar-Ilan DNA robots |work=[[Globes (newspaper)|Globes]] |url=https://en.globes.co.il/en/article-pfizer-to-collaborate-on-bar-ilan-dna-robots-1001036703 |date=May 14, 2015}}</ref> In June 2015, the company acquired Nimenrix and Mencevax, [[meningococcal vaccine]]s, from GlaxoSmithKline for around $130{{nbsp}}million.<ref>{{Cite news |title=Pfizer Buys Two GSK Meningitis Vaccines for $130M |url=https://www.genengnews.com/topics/drug-discovery/pfizer-buys-two-gsk-meningitis-vaccines-for-130m/ |website=genengnews.com |date=June 22, 2015}}</ref> In September 2015, Pfizer acquired [[Hospira]] for $17{{nbsp}}billion, including the assumption of debt.<ref>{{Cite press release |url=https://www.businesswire.com/news/home/20150903005752/en/Pfizer-Completes-Acquisition-of-Hospira |title=Pfizer Completes Acquisition of Hospira |publisher=Pfizer |via=[[Business Wire]] |date=September 3, 2015}}</ref><ref>{{Cite news |url=https://www.thepharmaletter.com/article/pfizer-completes-17-billion-hospira-acquisition |title=Pfizer completes $17-billion Hospira acquisition |work=[[The Pharma Letter]] |date=September 4, 2015}}</ref><ref>{{Cite news |first1=David |last1=Gelles |first2=Katie |last2=Thomas |title=Pfizer Bets $15 Billion on New Class of Generic Drugs |url=https://dealbook.nytimes.com/2015/02/05/pfizer-to-buy-hospira-a-drug-maker-for-15-2-billion-in-cash |work=The New York Times |date=February 5, 2015 |url-access=limited}}</ref><ref>{{Cite web |title=8-K |url=https://www.sec.gov/Archives/edgar/data/78003/000119312515037588/d866443d8k.htm |publisher=[[U.S. Securities and Exchange Commission]] |date=February 6, 2015}}</ref><ref>{{Cite press release |title=Pfizer to Acquire Hospira |url=https://www.pfizer.com/news/press-release/press-release-detail/pfizer_to_acquire_hospira |work=Pfizer |access-date=May 1, 2021 |archive-date=April 26, 2021 |archive-url=https://web.archive.org/web/20210426025941/https://www.pfizer.com/news/press-release/press-release-detail/pfizer_to_acquire_hospira |url-status=dead }}</ref><ref>{{Cite news |last=Neilan |first=Catherine |title=Pfizer, Hospira share prices to soar after $17bn deal announced |url=https://www.cityam.com/pfizer-hospira-share-prices-soar-after-17bn-deal-announced/ |work=[[City A.M.]] |date=February 5, 2015}}</ref> [[Hospira]] was the largest producer of generic injectable pharmaceuticals in the world.<ref>{{Cite news |title=US-based Hospira to buy Orchid Chemicals' injectables biz for $400 mn |url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/us-based-hospira-to-buy-orchid-chemicals-injectables-biz-for-400-mn/articleshow/5342003.cms |first1=Mohit |last1=Bhalla |first2=Khomba |last2=Singh |work=[[The Economic Times]] |date=December 16, 2009}}</ref> On November 23, 2015, Pfizer and [[Allergan]] announced a planned $160{{nbsp}}billion merger, in the largest pharmaceutical deal ever and the third largest corporate merger in history. The proposed transaction contemplated that the merged company maintain Allergan's [[Republic of Ireland]] domicile, resulting in the new company being subject to [[corporation tax]] at the relatively low rate of 12.5%.<ref>{{Cite news |title=Pfizer seals $160bn Allergan deal to create drugs giant |url=https://www.bbc.co.uk/news/business-34900344 |work=[[BBC News]] |date=November 23, 2015}}</ref> The deal was to constitute a [[reverse merger]], whereby Allergan acquired Pfizer, with the new company then changing its name to "Pfizer, plc".<ref>{{Cite news |title=Pfizer to buy Allergan in $160 billion deal |url=https://www.reuters.com/article/us-allergan-m-a-pfizer/pfizer-to-buy-allergan-in-160-billion-deal-idUSKBN0TB0UT20151124 |first1=Ransdell |last1=Pierson |first2=Bill |last2=Berkrot |work=Reuters |date=November 24, 2015}}</ref><ref>{{Cite news |title=Pfizer to Acquire Allergan for $160B |url=https://www.genengnews.com/news/pfizer-to-acquire-allergan-for-160b/ |work=genengnews.com |date=November 23, 2015}}</ref><ref>{{Cite news |first=Cynthia |last=Koons |title=Pfizer and Allergan to Combine With Joint Value of $160 Billion |url=https://www.bloomberg.com/news/articles/2015-11-22/pfizer-allergan-said-to-be-close-to-150-billion-merger |work=[[Bloomberg News]] |date=November 22, 2015 |url-access=limited}}</ref> On April 6, 2016, Pfizer and Allergan terminated the merger agreement after the [[Obama administration]] and the [[United States Department of the Treasury]] introduced new laws intended to limit [[corporate inversion]]s (the extent to which companies could move their headquarters overseas in order to reduce the amount of taxes they pay).<ref>{{Cite news |last=Bray |first=Chad |title=Pfizer and Allergan Call Off Merger After Tax-Rule Changes |url=https://www.nytimes.com/2016/04/07/business/dealbook/pfizer-allergan-merger.html |work=The New York Times |date=April 6, 2016 |url-access=limited}}</ref><ref>{{Cite news |last1=Humer |first1=Caroline |last2=Banerjee |first2=Ankur |title=Pfizer, Allergan scrap $160 billion deal after U.S. tax rule change |work=Reuters |url=https://www.reuters.com/article/us-allergan-m-a-pfizer-idUSKCN0X3188 |date=April 6, 2016}}</ref> | ||
In June 2016, the company acquired Anacor Pharmaceuticals for $5.2{{nbsp}}billion, expanding its portfolio in both inflammation and immunology drugs areas.<ref>{{cite press release |url=https://www.businesswire.com/news/home/20160624005299/en/Pfizer-Completes-Acquisition-of-Anacor |title=Pfizer Completes Acquisition of Anacor |publisher=Pfizer |via=[[Business Wire]] |date=June 24, 2016}}</ref><ref>{{Cite news |title=Pfizer to Acquire Anacor Pharmaceuticals for $5.2B |url=https://www.genengnews.com/news/pfizer-to-acquire-anacor-pharmaceuticals-for-5-2b/ |website=genengnews.com |date=May 16, 2016}}</ref> In August 2016, the company made a $40{{nbsp}}million bid for the assets of BIND Therapeutics, which was in [[bankruptcy]].<ref>{{Cite news |title=Pfizer Places High Bid of $40M for BIND Therapeutics |url=https://www.genengnews.com/news/pfizer-places-high-bid-of-40m-for-bind-therapeutics/ |website=genengnews.com |date=July 27, 2016}}</ref> The same month, the company acquired Bamboo Therapeutics for $645{{nbsp}}million, expanding its gene therapy offerings.<ref>{{Cite news |title=Pfizer Acquires Bamboo Therapeutics in a $645M Deal |url=https://www.genengnews.com/news/pfizer-acquires-bamboo-therapeutics-in-a-645m-deal/ |website=genengnews.com |date=August 1, 2016}}</ref> In September 2016, the company acquired cancer drug-maker [[Medivation]] for $14{{nbsp}}billion.<ref>{{Cite news |title=Pfizer to Acquire Medivation for $14B |url=https://www.genengnews.com/news/pfizer-to-acquire-medivation-for-14b/ |website=genengnews.com |date=August 22, 2016}}</ref><ref>{{Cite news |title=Pfizer to buy cancer drug firm Medivation for $14bn |work=[[BBC News]] |url=https://www.bbc.co.uk/news/business-37150531 |date=August 22, 2016}}</ref><ref>{{Cite press release |url=https://www.businesswire.com/news/home/20160928005824/en/ |title=Pfizer Completes Acquisition of Medivation |publisher=OncoImmune |via=[[Business Wire]] |date=September 28, 2016}}</ref> In October 2016, the company licensed the anti-[[CTLA4]] monoclonal antibody, ONC-392, from OncoImmune.<ref>{{Cite news |url=https://www.genengnews.com/topics/drug-discovery/oncoimmune-licenses-onc-392-to-pfizer-for-up-to-250m/ |title=OncoImmune Licenses ONC-392 to Pfizer for Up to $250M |work=genengnews.com |date=October 15, 2016}}</ref><ref>{{cite press release |url=https://www.businesswire.com/news/home/20160915005151/en/OncoImmune-Announces-Option-and-License-Agreement-with-Pfizer-Inc. |title=OncoImmune Announces Option and License Agreement with Pfizer Inc. |publisher=Pfizer |via=[[Business Wire]] |date=September 15, 2016}}</ref> In November 2016, Pfizer funded a $3,435,600 study with the [[CDC Foundation]] to research "screen-and-treat" strategies for [[cryptococcal disease]] in [[Botswana]].<ref name=":4">{{Cite web |date=2021-12-09 |title=CDC Foundation Active Programs October 1, 2020 – September 30, 2021 |url=https://www.cdcfoundation.org/CDCF-ActivePrograms-CDC-FY21?inline |url-status=live |archive-url=https://web.archive.org/web/20220115161004/https://www.cdcfoundation.org/CDCF-ActivePrograms-CDC-FY21?inline |archive-date=2022-01-15 |access-date=2022-08-06 |website=[[CDC Foundation]]}}</ref> In December 2016, Pfizer acquired [[AstraZeneca]]'s small-molecule antibiotics business for $1.575 billion.<ref>{{Cite press release |url=https://www.businesswire.com/news/home/20161222005395/en/Pfizer-Completes-Acquisition-of-Small-Molecule-Anti-Infective-Business-From-AstraZeneca |title=Pfizer Completes Acquisition of Small Molecule Anti-Infective Business From AstraZeneca |publisher=Pfizer |via=[[Business Wire]] |date=December 23, 2016}}</ref><ref>{{Cite news |title=Pfizer Buys AstraZeneca Antibiotics for Up to $1.575B |url=https://www.genengnews.com/topics/drug-discovery/pfizer-buys-astrazeneca-antibiotics-for-up-to-1-575b/ |website=genengnews.com |date=August 24, 2016}}</ref><ref>{{Cite magazine |title=Pfizer grabs AZ antibiotics in $1.5B deal. Pre-split prep or just another sales-boosting buy? |url=https://www.fiercepharma.com/pharma/pfizer-grabs-az-antibiotics-1-5b-deal-pre-split-prep-or-just-another-sales-boosting-buy |first=Tracy |last=Staton |magazine=Fierce Pharma |date=August 24, 2016}}</ref> | In June 2016, the company acquired Anacor Pharmaceuticals for $5.2{{nbsp}}billion, expanding its portfolio in both inflammation and immunology drugs areas.<ref>{{cite press release |url=https://www.businesswire.com/news/home/20160624005299/en/Pfizer-Completes-Acquisition-of-Anacor |title=Pfizer Completes Acquisition of Anacor |publisher=Pfizer |via=[[Business Wire]] |date=June 24, 2016}}</ref><ref>{{Cite news |title=Pfizer to Acquire Anacor Pharmaceuticals for $5.2B |url=https://www.genengnews.com/news/pfizer-to-acquire-anacor-pharmaceuticals-for-5-2b/ |website=genengnews.com |date=May 16, 2016}}</ref> In August 2016, the company made a $40{{nbsp}}million bid for the assets of BIND Therapeutics, which was in [[bankruptcy]].<ref>{{Cite news |title=Pfizer Places High Bid of $40M for BIND Therapeutics |url=https://www.genengnews.com/news/pfizer-places-high-bid-of-40m-for-bind-therapeutics/ |website=genengnews.com |date=July 27, 2016}}</ref> The same month, the company acquired Bamboo Therapeutics for $645{{nbsp}}million, expanding its gene therapy offerings.<ref>{{Cite news |title=Pfizer Acquires Bamboo Therapeutics in a $645M Deal |url=https://www.genengnews.com/news/pfizer-acquires-bamboo-therapeutics-in-a-645m-deal/ |website=genengnews.com |date=August 1, 2016}}</ref> In September 2016, the company acquired cancer drug-maker [[Medivation]] for $14{{nbsp}}billion.<ref>{{Cite news |title=Pfizer to Acquire Medivation for $14B |url=https://www.genengnews.com/news/pfizer-to-acquire-medivation-for-14b/ |website=genengnews.com |date=August 22, 2016}}</ref><ref>{{Cite news |title=Pfizer to buy cancer drug firm Medivation for $14bn |work=[[BBC News]] |url=https://www.bbc.co.uk/news/business-37150531 |date=August 22, 2016}}</ref><ref>{{Cite press release |url=https://www.businesswire.com/news/home/20160928005824/en/ |title=Pfizer Completes Acquisition of Medivation |publisher=OncoImmune |via=[[Business Wire]] |date=September 28, 2016}}</ref> In October 2016, the company licensed the anti-[[CTLA4]] monoclonal antibody, ONC-392, from OncoImmune.<ref>{{Cite news |url=https://www.genengnews.com/topics/drug-discovery/oncoimmune-licenses-onc-392-to-pfizer-for-up-to-250m/ |title=OncoImmune Licenses ONC-392 to Pfizer for Up to $250M |work=genengnews.com |date=October 15, 2016}}</ref><ref>{{cite press release |url=https://www.businesswire.com/news/home/20160915005151/en/OncoImmune-Announces-Option-and-License-Agreement-with-Pfizer-Inc. |title=OncoImmune Announces Option and License Agreement with Pfizer Inc. |publisher=Pfizer |via=[[Business Wire]] |date=September 15, 2016}}</ref> In November 2016, Pfizer funded a $3,435,600 study with the [[CDC Foundation]] to research "screen-and-treat" strategies for [[cryptococcal disease]] in [[Botswana]].<ref name=":4">{{Cite web |date=2021-12-09 |title=CDC Foundation Active Programs October 1, 2020 – September 30, 2021 |url=https://www.cdcfoundation.org/CDCF-ActivePrograms-CDC-FY21?inline |url-status=live |archive-url=https://web.archive.org/web/20220115161004/https://www.cdcfoundation.org/CDCF-ActivePrograms-CDC-FY21?inline |archive-date=2022-01-15 |access-date=2022-08-06 |website=[[CDC Foundation]]}}</ref> In December 2016, Pfizer acquired [[AstraZeneca]]'s small-molecule antibiotics business for $1.575 billion.<ref>{{Cite press release |url=https://www.businesswire.com/news/home/20161222005395/en/Pfizer-Completes-Acquisition-of-Small-Molecule-Anti-Infective-Business-From-AstraZeneca |title=Pfizer Completes Acquisition of Small Molecule Anti-Infective Business From AstraZeneca |publisher=Pfizer |via=[[Business Wire]] |date=December 23, 2016}}</ref><ref>{{Cite news |title=Pfizer Buys AstraZeneca Antibiotics for Up to $1.575B |url=https://www.genengnews.com/topics/drug-discovery/pfizer-buys-astrazeneca-antibiotics-for-up-to-1-575b/ |website=genengnews.com |date=August 24, 2016}}</ref><ref>{{Cite magazine |title=Pfizer grabs AZ antibiotics in $1.5B deal. Pre-split prep or just another sales-boosting buy? |url=https://www.fiercepharma.com/pharma/pfizer-grabs-az-antibiotics-1-5b-deal-pre-split-prep-or-just-another-sales-boosting-buy |first=Tracy |last=Staton |magazine=Fierce Pharma |date=August 24, 2016}}</ref> | ||
In January 2018, Pfizer announced that it would end its work on research into treatments for [[Alzheimer's disease]] and [[Parkinsonism]] (a symptom of [[Parkinson's disease]] and other conditions). The company said about 300 researchers would lose their jobs.<ref>{{Cite news |last=Hiltzik |first=Michael | author-link=Michael Hiltzik |title=Pfizer, pocketing a big tax cut from Trump, will end investment in Alzheimer's and Parkinson's research |url=https://www.latimes.com/business/hiltzik/la-fi-hiltzik-pfizer-20180108-story.html |work= | In January 2018, Pfizer announced that it would end its work on research into treatments for [[Alzheimer's disease]] and [[Parkinsonism]] (a symptom of [[Parkinson's disease]] and other conditions). The company said about 300 researchers would lose their jobs.<ref>{{Cite news |last=Hiltzik |first=Michael | author-link=Michael Hiltzik |title=Pfizer, pocketing a big tax cut from Trump, will end investment in Alzheimer's and Parkinson's research |url=https://www.latimes.com/business/hiltzik/la-fi-hiltzik-pfizer-20180108-story.html |work=Los Angeles Times |date=January 8, 2018 |url-access=subscription}}</ref> In July 2018, the [[Food and Drug Administration]] approved [[enzalutamide]], developed by Pfizer and [[Astellas Pharma]] for patients with [[castration]]-resistant [[prostate cancer]].<ref>{{Cite press release |url=https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-enzalutamide-castration-resistant-prostate-cancer |title=FDA approves enzalutamide for castration-resistant prostate cancer |publisher=[[Food and Drug Administration]] |date=July 13, 2018}}</ref> In August 2018, Pfizer signed an agreement with [[BioNTech]] to conduct joint research and development activities regarding [[mRNA]]-based [[influenza vaccine]]s.<ref>{{Cite press release |title=BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza |url=https://biontechse.gcs-web.com/news-releases/news-release-details/biontech-signs-collaboration-agreement-pfizer-develop-mrna-based |publisher=[[BioNTech]] |date=August 16, 2018}}</ref> In October 2018, effective January 1, 2019, [[Albert Bourla]] was promoted to [[chief executive officer]], succeeding [[Ian Read]], his mentor.<ref>{{Cite news |url=https://www.reuters.com/article/us-pfizer-ceo/pfizer-to-replace-longtime-ceo-read-with-veteran-bourla-idUSKCN1MB29D |title=Pfizer to replace longtime CEO Read with veteran Bourla |first1=Tamara |last1=Mathias |first2=Ankur |last2=Banerjee |date=October 1, 2018 |work=Reuters}}</ref><ref>{{cite news |last=Maidenberg |first=Micah |title=Pfizer Prepares for CEO Transition With Executive Suite Changes |url=https://www.wsj.com/articles/pfizer-prepares-for-ceo-transition-with-executive-suite-changes-1539095075 |work=The Wall Street Journal |date=October 9, 2018 |url-access=subscription}}</ref><ref>{{cite news |url=https://www.businessinsider.com/who-is-albert-bourla-next-pfizer-ceo-2018-10 |title=Pfizer's CEO is stepping down after 8 years — meet the man who will be replacing him |last=Ramsey |first=Lydia |work=[[Business Insider]] |date=October 1, 2018 |url-access=subscription}}</ref><ref>{{cite news |last=Jarvis |first=Lisa M. |title=Pfizer unveils CEO succession plan |work=[[Chemical & Engineering News]] |url=https://cen.acs.org/pharmaceuticals/Pfizer-unveils-CEO-succession-plan/96/i40 |date=October 3, 2018}}</ref> | ||
In July 2019, the company acquired Therachon for up to $810{{nbsp}}million, expanding its rare disease portfolio through Therachon's recombinant human fibroblast growth factor receptor 3 compound, aimed at treating conditions such as [[achondroplasia]].<ref>{{Cite news |url=https://www.spglobal.com/marketintelligence/en/news-insights/trending/sWCcSrMgL8UmeCJXuuGp-w2 |title=Pfizer completes acquisition of Therachon to bolster rare disease drug portfolio |first=Ravikash |last=Bakolia |work=[[S&P Global]] |date=July 1, 2019}}</ref> Also in July, Pfizer acquired [[Array Biopharma]] for $10.6{{nbsp}}billion, boosting its oncology pipeline.<ref>{{Cite press release |url=https://www.businesswire.com/news/home/20190730005590/en/Pfizer-Completes-Acquisition-of-Array-Biopharma |title=Pfizer Completes Acquisition of Array Biopharma |publisher=Pfizer |via=[[Business Wire]] |date=July 30, 2019}}</ref> In August 2019, Pfizer merged its consumer health business with that of GlaxoSmithKline, into a [[joint venture]] owned 68% by GlaxoSmithKline and 32% by Pfizer, with plans to make it a [[public company]]. The transaction built on a 2018 transaction where GlaxoSmithKline acquired [[Novartis]]' stake in the GSK-Novartis consumer healthcare joint business.<ref>{{Cite news |url=https://www.bbc.co.uk/news/business-46616713 |title=GlaxoSmithKline and Pfizer merge healthcare arms |work=[[BBC News]] |date=December 19, 2018}}</ref> The transaction followed negotiations with other companies including [[Reckitt Benckiser]],<ref>{{Cite magazine |title=Reckitt Benckiser's still keen on a Pfizer OTC buy. But can it afford one? |url=https://www.fiercepharma.com/pharma/reckitt-benckiser-s-still-keen-a-pfizer-otc-buy-but-can-it-afford-one |magazine=Fierce Pharma |first=Carly |last=Helfand |date=October 16, 2017}}</ref> [[Sanofi]], [[Johnson & Johnson]],<ref>{{Cite magazine |title=Sanofi, J&J could join GlaxoSmithKline, Reckitt in $20B bidding war for Pfizer OTC: report |url=https://www.fiercepharma.com/pharma/sanofi-j-j-could-join-gsk-reckitt-20b-bidding-war-for-pfizer-otc-report |magazine=Fierce Pharma |first=Carly |last=Helfand |date=October 26, 2017}}</ref> and [[Procter & Gamble]].<ref>{{Cite magazine |title=GlaxoSmithKline eyes Pfizer's OTC unit. But will a buy imperil its dividend? |url=https://www.fiercepharma.com/pharma/glaxosmithkline-s-eyeing-pfizer-s-otc-unit-but-will-a-buy-imperil-its-dividend |magazine=Fierce Pharma |first=Carly |last=Helfand |date=October 25, 2017}}</ref> In September 2019, Pfizer initiated a study with the [[CDC Foundation]] to investigate the tracking of [[healthcare-associated infection]]s, scheduled to run through to June 2023.<ref name=":4" /> In December 2019, Pfizer awarded the CDC Foundation a further $1,948,482 to continue its [[cryptococcal disease]] screening and treatment research in nine African countries.<ref name=":4" /> | In July 2019, the company acquired Therachon for up to $810{{nbsp}}million, expanding its rare disease portfolio through Therachon's recombinant human fibroblast growth factor receptor 3 compound, aimed at treating conditions such as [[achondroplasia]].<ref>{{Cite news |url=https://www.spglobal.com/marketintelligence/en/news-insights/trending/sWCcSrMgL8UmeCJXuuGp-w2 |title=Pfizer completes acquisition of Therachon to bolster rare disease drug portfolio |first=Ravikash |last=Bakolia |work=[[S&P Global]] |date=July 1, 2019}}</ref> Also in July, Pfizer acquired [[Array Biopharma]] for $10.6{{nbsp}}billion, boosting its oncology pipeline.<ref>{{Cite press release |url=https://www.businesswire.com/news/home/20190730005590/en/Pfizer-Completes-Acquisition-of-Array-Biopharma |title=Pfizer Completes Acquisition of Array Biopharma |publisher=Pfizer |via=[[Business Wire]] |date=July 30, 2019}}</ref> In August 2019, Pfizer merged its consumer health business with that of GlaxoSmithKline, into a [[joint venture]] owned 68% by GlaxoSmithKline and 32% by Pfizer, with plans to make it a [[public company]]. The transaction built on a 2018 transaction where GlaxoSmithKline acquired [[Novartis]]' stake in the GSK-Novartis consumer healthcare joint business.<ref>{{Cite news |url=https://www.bbc.co.uk/news/business-46616713 |title=GlaxoSmithKline and Pfizer merge healthcare arms |work=[[BBC News]] |date=December 19, 2018}}</ref> The transaction followed negotiations with other companies including [[Reckitt Benckiser]],<ref>{{Cite magazine |title=Reckitt Benckiser's still keen on a Pfizer OTC buy. But can it afford one? |url=https://www.fiercepharma.com/pharma/reckitt-benckiser-s-still-keen-a-pfizer-otc-buy-but-can-it-afford-one |magazine=Fierce Pharma |first=Carly |last=Helfand |date=October 16, 2017}}</ref> [[Sanofi]], [[Johnson & Johnson]],<ref>{{Cite magazine |title=Sanofi, J&J could join GlaxoSmithKline, Reckitt in $20B bidding war for Pfizer OTC: report |url=https://www.fiercepharma.com/pharma/sanofi-j-j-could-join-gsk-reckitt-20b-bidding-war-for-pfizer-otc-report |magazine=Fierce Pharma |first=Carly |last=Helfand |date=October 26, 2017}}</ref> and [[Procter & Gamble]].<ref>{{Cite magazine |title=GlaxoSmithKline eyes Pfizer's OTC unit. But will a buy imperil its dividend? |url=https://www.fiercepharma.com/pharma/glaxosmithkline-s-eyeing-pfizer-s-otc-unit-but-will-a-buy-imperil-its-dividend |magazine=Fierce Pharma |first=Carly |last=Helfand |date=October 25, 2017}}</ref> In September 2019, Pfizer initiated a study with the [[CDC Foundation]] to investigate the tracking of [[healthcare-associated infection]]s, scheduled to run through to June 2023.<ref name=":4" /> In December 2019, Pfizer awarded the CDC Foundation a further $1,948,482 to continue its [[cryptococcal disease]] screening and treatment research in nine African countries.<ref name=":4" /> | ||
| Line 160: | Line 160: | ||
===Late 2020–onwards: Corporate developments and acquisitions === | ===Late 2020–onwards: Corporate developments and acquisitions === | ||
In September 2020, the company acquired a 9.9% stake in CStone Pharmaceuticals for $200{{nbsp}}million (HK$1.55{{nbsp}}billion), helping to commercialise its anti-[[PD-L1]] monoclonal antibody, CS1001.<ref>{{Cite news |title=Pfizer to buy 9.9% of CStone for $200 million, eyes collaboration |url=https://www.reuters.com/article/us-cstone-pfizer/pfizer-to-buy-9-9-of-cstone-for-200-million-eyes-collaboration-idUKKBN26L01D |work= | In September 2020, the company acquired a 9.9% stake in CStone Pharmaceuticals for $200{{nbsp}}million (HK$1.55{{nbsp}}billion), helping to commercialise its anti-[[PD-L1]] monoclonal antibody, CS1001.<ref>{{Cite news |title=Pfizer to buy 9.9% of CStone for $200 million, eyes collaboration |url=https://www.reuters.com/article/us-cstone-pfizer/pfizer-to-buy-9-9-of-cstone-for-200-million-eyes-collaboration-idUKKBN26L01D |work=Reuters |date=September 29, 2020}}</ref> In October 2020, the company acquired Arixa Pharmaceuticals.<ref>{{Cite magazine |url=https://www.fiercebiotech.com/biotech/pfizer-snaps-up-antibiotics-maker-arixa-and-its-oral-avycaz-follow-up |title=Biotech Pfizer snaps up antibiotics maker Arixa and its oral Avycaz follow-up |first=Amirah |last=Al Idrus |magazine=Fierce Pharma |date=October 22, 2020}}</ref> In November 2020, using a [[Reverse Morris Trust]] structure, Pfizer merged its off-patent branded and [[generic drug]] business, known as Upjohn, with [[Mylan]] to form [[Viatris]], owned 57% by Pfizer shareholders.<ref>{{Cite news |url=https://www.nasdaq.com/articles/pfizer-completes-combination-of-upjohn-and-mylan-viatris-to-begin-trading-on-nov.-17-2020 |title=Pfizer Completes Combination Of Upjohn And Mylan; Viatris To Begin Trading On Nov. 17 |work=[[Nasdaq]] |date=November 16, 2020}}</ref><ref>{{Cite news |url=https://www.post-gazette.com/business/healthcare-business/2020/11/16/Mylan-merger-Upjohn-Viatris-bresch-coury-Pfizer-cost-cuts-generic-drugs/stories/202011160111 |title=Mylan completes merger with Upjohn to form Viatris |first=Patricia |last=Sabatini |work=[[Pittsburgh Post-Gazette]] |date=November 16, 2020}}</ref> | ||
On January 5, 2021, Pfizer introduced a new [[logo]].<ref>{{Cite news |last=Bruell |first=Alexandra |title=Pfizer Introduces New Logo Playing Up Role in Drug Creation |url=https://www.wsj.com/articles/pfizer-introduces-new-logo-playing-up-role-in-drug-creation-11609844400 |work=The Wall Street Journal |date=January 5, 2021 |issn=0099-9660 |url-access=subscription}}</ref> In April 2021, Pfizer acquired Amplyx Pharmaceuticals and its anti-fungal compound [[fosmanogepix]] (APX001).<ref>{{cite magazine |url=https://www.fiercebiotech.com/biotech/pfizer-buys-amplyx-to-grow-infectious-disease-pipeline |title=Pfizer buys Amplyx to grow infectious disease pipeline |first=Nick Paul |last=Taylor |magazine=Fierce Pharma |date=April 28, 2021}}</ref><ref>{{Cite news |url=https://www.sandiegouniontribune.com/business/biotech/story/2021-04-28/pfizer-acquires-fungus-fighting-san-diego-biotech-amplyx |title=Pfizer acquires fungus-fighting San Diego biotech |first=Jonathan |last=Wosen |work=[[The San Diego Union-Tribune]] |date=April 28, 2021}}</ref> In August, the company announced it would acquire Trillium Therapeutics Inc and its immuno-oncology portfolio for $2.3 billion.<ref>{{Cite news |url=https://www.reuters.com/business/pfizer-buy-trillium-therapeutics-226-bln-deal-2021-08-23/ |title=Pfizer to buy cancer drug developer Trillium in $2.3 BLN deal |newspaper=Reuters |date=August 23, 2021}}</ref><ref>{{Cite web |url=https://www.biospace.com/article/releases/pfizer-to-acquire-trillium-therapeutics-inc-/?s=79 |title=Pfizer to Acquire Trillium Therapeutics Inc}}</ref> | On January 5, 2021, Pfizer introduced a new [[logo]].<ref>{{Cite news |last=Bruell |first=Alexandra |title=Pfizer Introduces New Logo Playing Up Role in Drug Creation |url=https://www.wsj.com/articles/pfizer-introduces-new-logo-playing-up-role-in-drug-creation-11609844400 |work=The Wall Street Journal |date=January 5, 2021 |issn=0099-9660 |url-access=subscription}}</ref> In April 2021, Pfizer acquired Amplyx Pharmaceuticals and its anti-fungal compound [[fosmanogepix]] (APX001).<ref>{{cite magazine |url=https://www.fiercebiotech.com/biotech/pfizer-buys-amplyx-to-grow-infectious-disease-pipeline |title=Pfizer buys Amplyx to grow infectious disease pipeline |first=Nick Paul |last=Taylor |magazine=Fierce Pharma |date=April 28, 2021}}</ref><ref>{{Cite news |url=https://www.sandiegouniontribune.com/business/biotech/story/2021-04-28/pfizer-acquires-fungus-fighting-san-diego-biotech-amplyx |title=Pfizer acquires fungus-fighting San Diego biotech |first=Jonathan |last=Wosen |work=[[The San Diego Union-Tribune]] |date=April 28, 2021}}</ref> In August, the company announced it would acquire Trillium Therapeutics Inc and its immuno-oncology portfolio for $2.3 billion.<ref>{{Cite news |url=https://www.reuters.com/business/pfizer-buy-trillium-therapeutics-226-bln-deal-2021-08-23/ |title=Pfizer to buy cancer drug developer Trillium in $2.3 BLN deal |newspaper=Reuters |date=August 23, 2021}}</ref><ref>{{Cite web |url=https://www.biospace.com/article/releases/pfizer-to-acquire-trillium-therapeutics-inc-/?s=79 |title=Pfizer to Acquire Trillium Therapeutics Inc}}</ref> | ||
In March 2022, the company acquired [[Arena Pharmaceuticals]] for $6.7 billion in cash.<ref>{{Cite press release | url=https://www.businesswire.com/news/home/20220310005794/en/Pfizer-Completes-Acquisition-of-Arena-Pharmaceuticals | title=Pfizer Completes Acquisition of Arena Pharmaceuticals | publisher=[[Business Wire]] | date=March 11, 2022}}</ref><ref>{{cite web |title=Pfizer bets on Arena's promising bowel disease treatment in $6.7 bln deal |url=https://www.reuters.com/markets/deals/pfizer-acquire-arena-pharmaceuticals-67-bln-deal-2021-12-13 |work= | In March 2022, the company acquired [[Arena Pharmaceuticals]] for $6.7 billion in cash.<ref>{{Cite press release | url=https://www.businesswire.com/news/home/20220310005794/en/Pfizer-Completes-Acquisition-of-Arena-Pharmaceuticals | title=Pfizer Completes Acquisition of Arena Pharmaceuticals | publisher=[[Business Wire]] | date=March 11, 2022}}</ref><ref>{{cite web |title=Pfizer bets on Arena's promising bowel disease treatment in $6.7 bln deal |url=https://www.reuters.com/markets/deals/pfizer-acquire-arena-pharmaceuticals-67-bln-deal-2021-12-13 |work=Reuters |date=December 13, 2021 |access-date=December 13, 2021}}</ref><ref>{{cite web |title=Pfizer to Acquire Arena Pharmaceuticals in $6.7 Billion Deal |url=https://www.wsj.com/articles/pfizer-to-acquire-arena-pharmaceuticals-in-6-7-billion-deal-11639414813 |work=The Wall Street Journal |last=Walker |first=Joseph |date=December 13, 2021 |access-date=December 13, 2021}}</ref> In June 2022, the company acquired ReViral Ltd, for up to $525 million, gaining access to experimental drugs used to combat [[respiratory syncytial virus]] infections.<ref>{{Cite news | url=https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-buy-rsv-drug-developer-reviral-up-525-mln-2022-04-07/ | title=Pfizer boosts respiratory drug portfolio with ReViral purchase | newspaper=Reuters | date=April 7, 2022 | last1=Satija | first1=Bhanvi }}</ref><ref>{{Cite web |date=2022-06-10 |title=Pfizer acquires biopharma firm ReViral for up to $525m |url=https://www.pharmaceutical-technology.com/news/pfizer-acquires-biopharma-reviral/ |access-date=2022-06-10 |website=Pharmaceutical Technology }}</ref> In October 2022, the company acquired Biohaven Pharma and its [[calcitonin gene-related peptide]] programs for $11.6 billion.<ref>{{cite web | url=https://www.biospace.com/article/releases/pfizer-completes-acquisition-of-biohaven-pharmaceuticals/?s=110 | title=Pfizer Completes Acquisition of Biohaven Pharmaceuticals | date=October 3, 2022 }}</ref><ref>{{cite press release | url=https://www.businesswire.com/news/home/20220510005676/en/ | title=Pfizer to Acquire Biohaven Pharmaceuticals | date=May 10, 2022}}</ref><ref>{{cite web | url=https://www.biospace.com/article/pfizer-drops-a-cool-11-6-billion-on-migraine-leader-biohaven-/?s=79 | title=Pfizer Drops a Cool $11.6B on Migraine Leader Biohaven }}</ref> It also acquired Global Blood Therapeutics for $5.4 billion, boosting Pfizer's rare disease business.<ref>{{Cite press release | url=https://www.businesswire.com/news/home/20221004006158/en/Pfizer-Completes-Acquisition-of-Global-Blood-Therapeutics%C2%A0 | title=Pfizer Completes Acquisition of Global Blood Therapeutics | publisher=[[Business Wire]] | date=October 5, 2022}}</ref><ref>{{Cite news |last=Rockoff |first=Jonathan D. |date=2022-08-08 |title=Pfizer Agrees to $5.4 Billion Deal for Global Blood Therapeutics |work=The Wall Street Journal |url=https://www.wsj.com/articles/pfizer-reaches-5-4-billion-deal-for-global-blood-therapeutics-11659954601 |access-date=2022-08-08 |issn=0099-9660}}</ref><ref>{{Cite news |date=2022-08-08 |title=Flush with cash, Pfizer buys Global Blood Therapeutics in $5.4 billion deal |work=Reuters |url=https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-buy-global-blood-therapeutics-54-bln-deal-2022-08-08/ |access-date=2022-08-08}}</ref> | ||
In April 2023, Pfizer moved its world headquarters from [[42nd Street (Manhattan)|42nd Street]] in [[Midtown Manhattan]] to the Spiral at [[Hudson Yards (development)|Hudson Yards]].<ref>{{cite news |url=https://www.crainsnewyork.com/health-care/pfizer-opens-global-headquarters-hudson-yards-empty-offices-reach-pandemic-levels |last1=D'Ambrosio |first1=Amanda |title=Pfizer opens global headquarters in Hudson Yards as empty offices reach pandemic levels |work=[[Crain Communications]] |date=April 3, 2023}}</ref><ref>{{cite magazine |url=https://www.fiercepharma.com/pharma/pfizer-moves-west-side-settling-down-swanky-new-digs-hudson-yards-spiral-skyscraper |last1=Liu |first1=Angus |last2=Kansteiner |first2=Fraiser |title=Pfizer moves on up to the West Side, establishing new nerve center at Hudson Yards' Spiral skyscraper |magazine=Fierce Pharma |date=April 4, 2023}}</ref> | In April 2023, Pfizer moved its world headquarters from [[42nd Street (Manhattan)|42nd Street]] in [[Midtown Manhattan]] to the Spiral at [[Hudson Yards (development)|Hudson Yards]].<ref>{{cite news |url=https://www.crainsnewyork.com/health-care/pfizer-opens-global-headquarters-hudson-yards-empty-offices-reach-pandemic-levels |last1=D'Ambrosio |first1=Amanda |title=Pfizer opens global headquarters in Hudson Yards as empty offices reach pandemic levels |work=[[Crain Communications]] |date=April 3, 2023}}</ref><ref>{{cite magazine |url=https://www.fiercepharma.com/pharma/pfizer-moves-west-side-settling-down-swanky-new-digs-hudson-yards-spiral-skyscraper |last1=Liu |first1=Angus |last2=Kansteiner |first2=Fraiser |title=Pfizer moves on up to the West Side, establishing new nerve center at Hudson Yards' Spiral skyscraper |magazine=Fierce Pharma |date=April 4, 2023}}</ref> | ||
In December 2023, the company acquired [[Seagen]], a pioneer of [[antibody–drug conjugate]]s for the treatment of cancer, for $43{{nbsp}}billion.<ref>{{cite news |last=Mishra |first=Manas |date=2022-03-13 |title=Pfizer signs $43 bln Seagen deal in cancer drug push |url=https://www.reuters.com/markets/deals/pfizer-buy-seagen-deal-valued-43-billion-2023-03-13/ |publisher= | In December 2023, the company acquired [[Seagen]], a pioneer of [[antibody–drug conjugate]]s for the treatment of cancer, for $43{{nbsp}}billion.<ref>{{cite news |last=Mishra |first=Manas |date=2022-03-13 |title=Pfizer signs $43 bln Seagen deal in cancer drug push |url=https://www.reuters.com/markets/deals/pfizer-buy-seagen-deal-valued-43-billion-2023-03-13/ |publisher=Reuters}}</ref><ref>{{Cite press release | url=https://www.businesswire.com/news/home/20231213759493/en/Pfizer-Completes-Acquisition-of-Seagen | title=Pfizer Completes Acquisition of Seagen | publisher=[[Business Wire]] | date=December 14, 2023}}</ref> | ||
On Sept 30, 2024, Pfizer announced its intentions to sell 540 million Haleon shares whose worth is about £2.1 billion ($2.8 billion) according to Bloomberg calculations.<ref>{{Cite web |date=October 1, 2024 |title=Pfizer to further reduce stake in Haleon, offers to sell 540 million share |url=https://www.business-standard.com/world-news/pfizer-to-further-reduce-stake-in-haleon-offers-to-sell-540-million-share-124100101515_1.html}}</ref> | On Sept 30, 2024, Pfizer announced its intentions to sell 540 million Haleon shares whose worth is about £2.1 billion ($2.8 billion) according to Bloomberg calculations.<ref>{{Cite web |date=October 1, 2024 |title=Pfizer to further reduce stake in Haleon, offers to sell 540 million share |url=https://www.business-standard.com/world-news/pfizer-to-further-reduce-stake-in-haleon-offers-to-sell-540-million-share-124100101515_1.html}}</ref> | ||
| Line 282: | Line 282: | ||
===2012 Celebrex intellectual property settlement=== | ===2012 Celebrex intellectual property settlement=== | ||
[[Brigham Young University]] (BYU) said a professor of chemistry, Dr. [[Daniel L. Simmons]], discovered an enzyme in the 1990s that led towards development of [[Celebrex]]. BYU was originally seeking a 15% royalty on sales, equating to $9.7{{nbsp}}billion. A research agreement had been made between BYU and [[Monsanto]], whose pharmaceutical business was later acquired by Pfizer, to develop a better [[aspirin]]. The enzyme Dr. Simmons claims to have discovered would induce pain and inflammation while causing gastrointestinal problems and Celebrex is used to reduce those issues. A six-year battle ensued because BYU claimed that Pfizer did not give Dr. Simmons credit or compensation, while Pfizer claimed that it had met all obligations regarding the Monsanto agreement. In May 2012, Pfizer settled the allegations, agreeing to pay $450{{nbsp}}million.<ref>{{cite news |url=https://www.nytimes.com/2012/05/02/health/pfizer-settles-byu-lawsuit-over-development-of-celebrex.html |title=Pfizer Settles B.Y.U. Lawsuit Over Development of Celebrex |agency= | [[Brigham Young University]] (BYU) said a professor of chemistry, Dr. [[Daniel L. Simmons]], discovered an enzyme in the 1990s that led towards development of [[Celebrex]]. BYU was originally seeking a 15% royalty on sales, equating to $9.7{{nbsp}}billion. A research agreement had been made between BYU and [[Monsanto]], whose pharmaceutical business was later acquired by Pfizer, to develop a better [[aspirin]]. The enzyme Dr. Simmons claims to have discovered would induce pain and inflammation while causing gastrointestinal problems and Celebrex is used to reduce those issues. A six-year battle ensued because BYU claimed that Pfizer did not give Dr. Simmons credit or compensation, while Pfizer claimed that it had met all obligations regarding the Monsanto agreement. In May 2012, Pfizer settled the allegations, agreeing to pay $450{{nbsp}}million.<ref>{{cite news |url=https://www.nytimes.com/2012/05/02/health/pfizer-settles-byu-lawsuit-over-development-of-celebrex.html |title=Pfizer Settles B.Y.U. Lawsuit Over Development of Celebrex |agency=Associated Press |work=The New York Times |date=May 1, 2012 |url-access=limited}}</ref> | ||
===2011 Nigeria Trovafloxacin lawsuit settlement=== | ===2011 Nigeria Trovafloxacin lawsuit settlement=== | ||
| Line 381: | Line 381: | ||
* [[World Economic Forum]] – Member organization.<ref>{{Cite web |last=Ivan |first=Wecke |date=2021-08-16 |title=Conspiracy theories aside, there is something fishy about the Great Reset |url=https://www.opendemocracy.net/en/oureconomy/conspiracy-theories-aside-there-something-fishy-about-great-reset/ |url-status=live |archive-url=https://archive.today/20220404023305/https://www.opendemocracy.net/en/oureconomy/conspiracy-theories-aside-there-something-fishy-about-great-reset/ |archive-date=April 4, 2022 |access-date=2022-04-08 |website=openDemocracy }}</ref><ref>{{Cite web |title=Pfizer |url=https://www.weforum.org/organizations/pfizer/ |url-status=live |archive-url=https://archive.today/20220314092916/https://www.weforum.org/organizations/pfizer |archive-date=March 14, 2022 |access-date=2022-04-06 |website=World Economic Forum }}</ref> | * [[World Economic Forum]] – Member organization.<ref>{{Cite web |last=Ivan |first=Wecke |date=2021-08-16 |title=Conspiracy theories aside, there is something fishy about the Great Reset |url=https://www.opendemocracy.net/en/oureconomy/conspiracy-theories-aside-there-something-fishy-about-great-reset/ |url-status=live |archive-url=https://archive.today/20220404023305/https://www.opendemocracy.net/en/oureconomy/conspiracy-theories-aside-there-something-fishy-about-great-reset/ |archive-date=April 4, 2022 |access-date=2022-04-08 |website=openDemocracy }}</ref><ref>{{Cite web |title=Pfizer |url=https://www.weforum.org/organizations/pfizer/ |url-status=live |archive-url=https://archive.today/20220314092916/https://www.weforum.org/organizations/pfizer |archive-date=March 14, 2022 |access-date=2022-04-06 |website=World Economic Forum }}</ref> | ||
[[Scott Gottlieb]], who resigned as [[FDA commissioner]] in April 2019, joined the Pfizer [[board of directors]] three months later, in July 2019.<ref>{{Cite news |last=Mishra |first=Manas |date=July 2, 2019 |title=Senator Warren asks former FDA chief Gottlieb to resign from Pfizer board |work= | [[Scott Gottlieb]], who resigned as [[FDA commissioner]] in April 2019, joined the Pfizer [[board of directors]] three months later, in July 2019.<ref>{{Cite news |last=Mishra |first=Manas |date=July 2, 2019 |title=Senator Warren asks former FDA chief Gottlieb to resign from Pfizer board |work=Reuters |editor-last=Kuber |editor-first=Shailesh |url=https://www.reuters.com/article/us-pfizer-board-scott-gottlieb/senator-warren-asks-former-fda-chief-gottlieb-to-resign-from-pfizer-board-idUSKCN1TX2IX}}</ref> | ||
Pfizer lobbied various officials in the [[Government of British Columbia]] between April and November 2012, including then-premier [[Christy Clark]], future premier [[John Horgan]], future health minister [[Adrian Dix]], and future deputy premier, minister of public safety and solicitor general [[Mike Farnworth]]. The disclosed purpose was to "provide health policy and pharmaceutical information and communications on behalf of Pfizer Canada," and "learn and understand the budgetary, policy and strategic directions of the Government."<ref>{{Cite web |last= |first= |date=2012-04-10 |title=Registration ID: 200777 |url=https://www.lobbyistsregistrar.bc.ca/app/secure/orl/lrs/do/vwRg?cno=2406®Id=200777 |url-status=live |archive-url=https://archive.today/20220426232441/https://www.lobbyistsregistrar.bc.ca/app/secure/orl/lrs/do/vwRg?cno=2406®Id=200777 |archive-date=April 26, 2022 |access-date=2022-04-26 |website=BC Office of the Registrar of Lobbyists }}</ref> | Pfizer lobbied various officials in the [[Government of British Columbia]] between April and November 2012, including then-premier [[Christy Clark]], future premier [[John Horgan]], future health minister [[Adrian Dix]], and future deputy premier, minister of public safety and solicitor general [[Mike Farnworth]]. The disclosed purpose was to "provide health policy and pharmaceutical information and communications on behalf of Pfizer Canada," and "learn and understand the budgetary, policy and strategic directions of the Government."<ref>{{Cite web |last= |first= |date=2012-04-10 |title=Registration ID: 200777 |url=https://www.lobbyistsregistrar.bc.ca/app/secure/orl/lrs/do/vwRg?cno=2406®Id=200777 |url-status=live |archive-url=https://archive.today/20220426232441/https://www.lobbyistsregistrar.bc.ca/app/secure/orl/lrs/do/vwRg?cno=2406®Id=200777 |archive-date=April 26, 2022 |access-date=2022-04-26 |website=BC Office of the Registrar of Lobbyists }}</ref> | ||